Microbot Medical (Nasdaq: MBOT) announced its first North Carolina-based customer for the LIBERTY Endovascular Robotic System. This leading academic healthcare system, operating a multi-hospital network across the state, becomes the first user in the Southeast/Mid-Atlantic region and adds to a growing roster of adopting health systems.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MBOT
+1.52%
1 alert
+1.52%Session close to close
$132.99MMarket Cap
10.28KVolume
In the Jun 2 session, MBOT gained 1.52%, reflecting a mild positive market reaction.
This announcement adds another U.S. healthcare system, spanning a multi-hospital North Carolina netw...
Analysis
This announcement adds another U.S. healthcare system, spanning a multi-hospital North Carolina network, to the growing roster of LIBERTY users, reinforcing the Full Market Release narrative. It follows first commercial revenue of $105,000, international clearance in Israel, and expanded commercial leadership for EMEA. At the same time, Microbot posted a $3.7 million quarterly net loss and put in place an at-the-market equity program of up to $39,230,691, so execution pace and financing usage remain key metrics to monitor.
Key Figures
Q1 2026 revenue:$105,000Q1 2026 cost of revenues:$103,000Q1 2026 net loss:$3.7 million+5 more
8 metrics
Q1 2026 revenue$105,000First commercial revenue from LIBERTY system, quarter ended Mar 31, 2026
Q1 2026 cost of revenues$103,000Quarter ended Mar 31, 2026
Q1 2026 net loss$3.7 millionWider than $2.6 million loss a year earlier
Cash$3.7 millionCash and cash equivalents as of Mar 31, 2026
Marketable securities$68.8 millionAs of Mar 31, 2026
ATM program size$39,230,691Maximum aggregate offering price under 2026-04-10 at-the-market offering
Shares outstanding67,158,044 sharesCommon shares outstanding as of Dec 31, 2025
As-adjusted shares83,851,955 sharesAssumes sale of 16,693,911 shares at $2.35 in ATM
Appointment of EMEA sales VP and update on FDA clearance and CE plans.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Commercial and adoption updates have sometimes seen negative or muted reactions, while regulatory and strategic expansion news have more often aligned positively with price.
Recent Company History
Over recent months, Microbot has progressed from limited to Full Market Release of the LIBERTY system, reporting its first commercial revenue of $105,000 and expanding adoption across multiple U.S. states. Regulatory momentum included first international clearance in Israel, while management strengthened commercial leadership for EMEA. Some positive commercial milestones, such as the Q1 revenue update, saw share-price declines, whereas regulatory approval in Israel produced a 5.85% gain. Today’s new North Carolina system adds to this ongoing commercialization narrative.
"developer and distributor of the innovative LIBERTY® Endovascular Robotic System"
Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.
robotic systemtechnical
"LIBERTY® Endovascular Robotic System, announced that it has secured its first"
A robotic system is a combination of machines, sensors and software that carries out physical tasks with various levels of independence — from guided arms on factory floors to medical robots that assist surgeons. For investors, robotic systems matter because they can lower labor costs, boost speed and precision, or enable new products and services; like a smart, tireless worker, they can change a company’s productivity, margins and growth potential.
peripheral endovascular proceduresmedical
"single-use, remotely operated robotic system for peripheral endovascular procedures"
Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.
prostatic artery embolizationmedical
"procedures, including PAE for BPH, GAE for chronic knee pain and Y-90"
Prostatic artery embolization is a minimally invasive procedure that reduces blood flow to parts of the prostate by selectively blocking the small arteries that feed it, causing the enlarged tissue to shrink. For investors, it matters because it represents a non-surgical alternative for treating urinary symptoms from prostate enlargement, affecting demand for medical devices, imaging equipment, specialist services, and reimbursement decisions in the urology and interventional radiology markets.
y-90 radioembolizationmedical
"GAE for chronic knee pain and Y-90 radioembolization for liver cancer"
Y-90 radioembolization is a medical procedure that delivers tiny beads carrying the radioactive atom yttrium-90 directly into blood vessels feeding liver tumors, where they lodge and emit focused radiation that shrinks or destroys cancer cells. For investors, it matters because adoption, clinical results, device makers, and reimbursement shape revenue potential and competitive dynamics in the market for liver cancer treatments—think of it as a targeted missile system for tumors rather than broad-area radiation.
ce markregulatory
"expects a CE mark by end of 2026; Europe procedure volume is cited"
A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.
at-the-market offeringfinancial
"proposes an at-the-market offering to sell up to $39,230,691 aggregate"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
form s-3 registration statementregulatory
"filed Amendment No. 1 to its Form S-3 registration statement"
Form S-3 registration statement is a short-form filing with the U.S. Securities and Exchange Commission that lets companies already reporting to the regulator register new securities for sale using streamlined disclosure instead of a full prospectus. It matters to investors because it allows a company to raise capital more quickly and with less paperwork—like having a pre-approved menu to order from when cash is needed—which can affect share dilution, trading liquidity, and market perception of the firm's financial flexibility.
A leading academic center becomes the first user in the Southeast, Mid-Atlantic region
HINGHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has secured its first North Carolina-based customer, becoming the latest healthcare system to adopt the LIBERTY System, demonstrating a broadening geographic penetration from the Southeast, Mid-Atlantic and Northeast U.S. The Company’s latest account delivers state of the art patient care through a multi-hospital network that encompasses the entire state and joins a growing roster of health systems that we believe recognize the unique benefits of the LIBERTY system.
“It’s exciting to see the pace of increase in new accounts following the full market release of the LIBERTY system, including our newest territories in the Northeast and South-Atlantic, as some of the nation’s leading health systems are adopting LIBERTY system,” commented Harel Gadot, CEO, President and Chairman. “The recent new account addition is another significant development for Microbot and represents continued execution of our commercial strategy, and we expect to penetrate other major metropolitan markets with some of the leading academic institutions in the U.S. adopting the LIBERTY system.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
What did Microbot Medical (MBOT) announce on June 2, 2026 about the LIBERTY system?
Microbot Medical announced securing its first North Carolina-based customer for the LIBERTY Endovascular Robotic System. According to Microbot Medical, this healthcare system joins a growing roster of health systems adopting LIBERTY following its full market release in the United States.
Why is the first North Carolina healthcare system adoption important for Microbot Medical (MBOT)?
The first North Carolina adoption expands LIBERTY’s footprint into a statewide multi-hospital network. According to Microbot Medical, this account supports broader geographic penetration across the Southeast, Mid-Atlantic and Northeast regions, aligning with the company’s commercial strategy for the LIBERTY Endovascular Robotic System.
How does the new LIBERTY system account affect Microbot Medical’s U.S. market penetration?
The new account broadens LIBERTY’s presence into North Carolina and the Southeast/Mid-Atlantic region. According to Microbot Medical, leading health systems in the Northeast and South-Atlantic are adopting LIBERTY, reflecting increasing account additions after the product’s full market release.
What type of healthcare organization adopted Microbot Medical’s LIBERTY Endovascular Robotic System in North Carolina?
The new LIBERTY customer is described as a leading academic center with a multi-hospital network. According to Microbot Medical, this system delivers state-of-the-art patient care across North Carolina and becomes part of a growing group of health systems using the LIBERTY technology.
What are Microbot Medical’s future commercial plans for the LIBERTY system after this North Carolina deal?
Microbot Medical expects to penetrate other major U.S. metropolitan markets with LIBERTY. According to Microbot Medical, the company anticipates additional adoption by leading academic institutions as it continues executing its commercial strategy following the full market release of the LIBERTY Endovascular Robotic System.
